Diadia
Our TechnologyResearchResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

inflammation · Mechanism Report

Can FADS1 and FADS2 variants influence inflammatory lipid mediator substrates?

FADS1 and FADS2 variants can alter long-chain fatty-acid synthesis and shift the substrates available for inflammatory and inflammation-resolving mediators.

PlausibleNovember 18, 202610 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

FADS1 and FADS2 variants can alter long-chain polyunsaturated fatty-acid synthesis and thereby influence the substrate balance for inflammatory and inflammation-resolving lipid mediators.

laying out figure…
2 of 4 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

These variants are associated with differences in fatty-acid conversion and estimated desaturase activity. Changes in long-chain fatty-acid availability may affect mediator precursors, but do not predict an individual's inflammatory state or clinical outcomes.

Verified conclusion

At age 52, this claim is biologically well supported: common variation in the FADS1/FADS2 region can change endogenous long-chain polyunsaturated fatty-acid (PUFA) handling, which in turn changes the lipid substrates available to inflammatory and resolution-related mediator pathways. This describes metabolic potential, not a proven prediction of inflammation or clinical outcomes for an individual.

Genetic and metabolic evidence

  • FADS1 rs174537 G associates with higher arachidonic acid (AA), lower dihomo-γ-linolenic acid (DGLA), and a higher AA/DGLA ratio, a proxy for Δ5-desaturase activity. In one European-descent founder cohort, it explained 24% of variation in the reported n-6 FADS1 activity ratio.
  • For FADS2, rs1535 G was associated with lower estimated activity: AA/linoleic-acid ratios declined from 2.01 (AA) to 1.76 (AG) and 1.62 (GG) in a post-myocardial-infarction cohort.
  • Controlled feeding studies provide functional corroboration: EPA rose with high α-linolenic-acid intake only in rs174550 TT participants in one randomized trial, and AA responses to high linoleic-acid intake differed by genotype.

Mediator-substrate implications

  • AA is a substrate for inflammatory eicosanoid pathways, whereas EPA and DHA supply omega-3-derived oxylipins and precursors of specialized pro-resolving mediators.
  • In a 12-month randomized trial of adults with low fish intake, higher EPA+DHA intake dose-dependently increased EPA/DHA-derived oxylipins, including 17-HDHA and 18-HEPE, precursors of resolution mediators.
  • FADS-locus variants also track with lower long-chain-PUFA-containing lipid species and relatively higher precursor species, consistent with a shifted substrate pool.

Mechanistic interpretation

  • Genotype-associated product:precursor ratios indicate altered estimated desaturase activity, although these ratios are surrogates rather than direct enzyme assays.
  • Changes in conversion of dietary linoleic acid or α-linolenic acid to downstream PUFAs offer a plausible route by which genotype modifies mediator precursors.

Bottom line

  • FADS1/FADS2 variants can alter long-chain PUFA synthesis and plausibly shift substrates for both inflammatory and inflammation-resolving lipid mediators. They do not, by themselves, establish an individual’s inflammatory state, mature specialized pro-resolving mediator levels, or a need for genotype-guided supplementation.

References

  1. The FADS1 rs174550 Genotype Modifies the n‐3 and n‐6 PUFA ... — pmc.ncbi.nlm.nih.gov ↗
  2. The impact of fatty acid desaturase genotype on ... — cambridge.org ↗
  3. FADS genetic variants and ω-6 polyunsaturated fatty acid ... — pmc.ncbi.nlm.nih.gov ↗
  4. Genetic variation in polyunsaturated fatty acid metabolism and its ... — pmc.ncbi.nlm.nih.gov ↗
  5. journals.plos.org · plosone · articleGenetic profiling of fatty acid desaturase polymorphisms ... — journals.plos.org ↗
  6. Polyunsaturated fatty acid levels in blood during pregnancy, at birth and at 7 years: their associations with two common FADS2 polymorphisms — pmc.ncbi.nlm.nih.gov ↗
  7. Plasma oxylipins respond in a linear dose-response manner with increased intake of EPA and DHA: results from a randomized controlled trial in healthy humans — ora.ox.ac.uk ↗
  8. FADS genetic and metabolomic analyses identify the ∆5 desaturase (FADS1) step as a critical control point in the formation of biologically important lipids - Scientific Reports — link.springer.com ↗
  9. Genetic variation at the FADS1-FADS2 gene locus ... — pubmed.ncbi.nlm.nih.gov ↗
  10. Beneficial Outcomes of Omega-6 and Omega-3 Polyunsaturated Fatty Acids ... — pmc.ncbi.nlm.nih.gov ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible6 sourcesCan chronic osteomyelitis and deep wound infections sustain systemic inflammation?→Supported9 sourcesCan an oral infection cause systemic inflammation or a remote Klebsiella wound infection?→